14-day Premium Trial Subscription Try For FreeTry Free
$4.57
+0.160 (+3.63%)
At Close: May 01, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $4.25 $5.48 Wednesday, 1st May 2024 QURE stock ended at $4.57. This is 3.63% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 6.31% from a day low at $4.36 to a day high of $4.64.
90 days $4.25 $6.85
52 weeks $4.25 $22.48

Historical uniQure N.V. prices

Date Open High Low Close Volume
Nov 03, 2021 $33.63 $36.13 $33.54 $35.90 595 740
Nov 02, 2021 $31.50 $34.53 $31.00 $34.11 643 495
Nov 01, 2021 $30.63 $31.75 $30.52 $31.70 273 822
Oct 29, 2021 $30.55 $30.68 $29.96 $30.47 293 499
Oct 28, 2021 $29.21 $30.71 $29.11 $30.65 494 468
Oct 27, 2021 $29.35 $29.51 $28.36 $29.06 521 943
Oct 26, 2021 $29.65 $29.69 $28.07 $28.38 382 691
Oct 25, 2021 $28.10 $29.58 $27.92 $29.36 617 733
Oct 22, 2021 $28.27 $28.46 $27.74 $28.46 450 130
Oct 21, 2021 $28.59 $28.69 $28.03 $28.24 328 421
Oct 20, 2021 $28.53 $28.87 $28.20 $28.47 282 339
Oct 19, 2021 $28.37 $28.92 $27.85 $28.53 434 790
Oct 18, 2021 $29.72 $29.87 $28.24 $28.27 407 885
Oct 15, 2021 $30.65 $30.65 $29.89 $30.06 259 888
Oct 14, 2021 $30.64 $31.09 $30.36 $30.64 372 191
Oct 13, 2021 $30.60 $31.01 $30.17 $30.31 247 736
Oct 12, 2021 $30.44 $30.96 $30.21 $30.60 213 803
Oct 11, 2021 $30.44 $31.19 $30.22 $30.39 294 056
Oct 08, 2021 $31.22 $31.49 $30.27 $30.45 279 294
Oct 07, 2021 $31.52 $31.88 $30.80 $31.21 331 768
Oct 06, 2021 $31.04 $31.92 $30.53 $31.33 360 674
Oct 05, 2021 $31.05 $31.51 $30.77 $31.33 306 771
Oct 04, 2021 $31.95 $32.76 $30.68 $31.10 282 238
Oct 01, 2021 $31.96 $32.23 $31.43 $32.03 537 981
Sep 30, 2021 $31.52 $32.43 $31.52 $32.01 325 940
Click to get the best stock tips daily for free!

About uniQure N.V.

uniQure N.V. uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phas... QURE Profile

Golden Star

Ticker Date Change Price
HRB Apr 29 1.00% $47.23
LYG Apr 29 0.391% $2.56
ORA Apr 29 1.95% $64.48
ETSY Apr 26 3.43% $67.43
DHT Apr 24 0.98% $11.28
LPLA Apr 19 1.10% $262.59
MLI Apr 19 7.29% $52.28
PFLT Apr 18 1.33% $11.25
DOOR Apr 18 0.94% $131.39
OCSL Apr 17 0.360% $19.43
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT